<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Rasagiline</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01367</strong>&#160; (EXPT02758)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson&#8217;s disease or as an adjunct therapy in more advanced cases.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01367/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01367/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01367.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01367.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01367.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01367.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01367.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01367">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>RAS</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Azilect</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/neuroprotective-agents">Neuroprotective Agents</a></li>
<li><a href="/mesh/monoamine-oxidase-inhibitors">Monoamine Oxidase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>136236-51-6</td></tr><tr><th>Weight</th><td>Average: 171.2383<br>Monoisotopic: 171.104799421</td></tr><tr><th>Chemical Formula</th><td>C<sub>12</sub>H<sub>13</sub>N</td></tr><tr><th>InChI Key</th><td>RUOKEQAAGRXIBM-GFCCVEGCSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">C#CCN[C@@H]1CCC2=CC=CC=C12</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Indanes</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Indanes</td></tr><tr><th>Alternative parents</th><td>Benzene and Substituted Derivatives; Dialkylamines; Polyamines</td></tr><tr><th>Substituents</th><td>benzene; secondary aliphatic amine; polyamine; secondary amine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the indanes. These are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.</td></tr><tr><th>Pharmacodynamics</th><td>Rasagiline is a propargylamine and an irreversible inhibitor of monoamine oxidase (MAO). MAO, a flavin-containing enzyme, regulates the metabolic degradation of catecholamines and serotonin in the CNS and peripheral tissues. It is classified into two major molecular species, A and B, and is localized in mitochondrial membranes throughout the body in nerve terminals, brain, liver and intestinal mucosa. MAO-A is found predominantly in the GI tract and liver, and regulates the metabolic degradation of circulating catecholamines and dietary amines. MAO-B is the major form in the human brain and is responsible for the regulation of the metabolic degradation of dopamine and phenylethylamine. In ex vivo animal studies in brain, liver and intestinal tissues rasagiline was shown to be a potent,selective, and irreversible monoamine oxidase type B (MAO-B) inhibitor. At the recommended therapeutic doses, Rasagiline was also shown to be a potent and irreversible inhibitor of MAO-B in platelets. The selectivity of rasagiline for inhibiting only MAO-B (and not MAO-A) in humans and the sensitivity to tyramine during rasagiline treatment at any dose has not been sufficiently characterized to avoid restriction of dietary tyramine and amines contained in medications.</td></tr><tr><th>Mechanism of action</th><td>The precise mechanisms of action of rasagiline is unknown. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline's beneficial effects seen in models of dopaminergic motor dysfunction.</td></tr><tr><th>Absorption</th><td>Rasagiline is rapidly absorbed following oral administration.  The absolute bioavailability of rasagiline is about 36%.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>87 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>Plasma protein binding ranges from 88-94% with mean extent of binding of 61-63% to human albumin over the concentration range of 1-100 ng/ml.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Rasagiline undergoes almost complete biotransformation in the liver prior to excretion. In vitro experiments indicate that both routes of rasagiline metabolism are dependent on the cytochrome P450 (CYP) system, with CYP 1A2 being the major isoenzyme involved in rasagiline metabolism.</p></td></tr><tr><th>Route of elimination</th><td>Rasagiline undergoes almost complete biotransformation in the liver prior to excretion. Glucuronide conjugation of rasagiline and its metabolites, with subsequent urinary excretion, is the major elimination pathway. After oral administration of 14C-labeled rasagiline, elimination occurred primarily via urine and secondarily via feces (62% of total dose in urine and 7% of total dose in feces over 7 days), with a total calculated recovery of 84% of the dose over a period of 38 days. Less than 1% of rasagiline was excreted as unchanged drug in urine.</td></tr><tr><th>Half life</th><td>Rasagiline has a mean steady-state half life of 3 hours but there is no correlation of pharmacokinetics with its pharmacological effect because of its irreversible inhibition of MAO-B.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Signs and symptoms of overdosage may include, alone or in combination, any of the following: drowsiness, dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, trismus, opisthotonos, convulsions, and coma; rapid and irregular pulse, hypertension, hypotension and vascular collapse; precordial pain, respiratory depression and failure, hyperpyrexia, diaphoresis, and cool, clammy skin.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9901</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9782</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5585</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.661</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7409</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7116</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5584</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8037</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.5724</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6928</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9037</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8259</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.6769</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.5689</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8542</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.534</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6468
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8959
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.6073
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.8164 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.7804
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7137
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Teva neuroscience inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td>0.5 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>1 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00488">Altretamine</a></td><td>Risk of severe hypotension</td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB00182">Amphetamine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00289">Atomoxetine</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00865">Benzphetamine</a></td><td>MAO Inhibitors may enhance the hypertensive effect of Amphetamines. Concomitant use of amphetamines and monoamine oxidase inhibitors (MAOI) should be avoided. If used concomitantly, careful monitoring of blood pressure must occur. It may take up to 2 weeks after the discontinuation of an MAOI for the effects to dissipate enough to afford safety to the administration of interacting agents. </td></tr><tr><td><a href="/drugs/DB01393">Bezafibrate</a></td><td>MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) rasagiline. </td></tr><tr><td><a href="/drugs/DB00484">Brimonidine</a></td><td>MAO Inhibitors like rasagiline may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. </td></tr><tr><td><a href="/drugs/DB00921">Buprenorphine</a></td><td>Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like rasagiline. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. </td></tr><tr><td><a href="/drugs/DB01156">Bupropion</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00490">Buspirone</a></td><td>Possible blood pressure elevation</td></tr><tr><td><a href="/drugs/DB00537">Ciprofloxacin</a></td><td>Ciprofloxacin, a strong CYP1A2 inhibitor, may decrease the metabolism of rasagiline. Monitor for changes in the therapeutic and adverse effects of rasagiline if ciprofloxacin is initiated or discontinued.</td></tr><tr><td><a href="/drugs/DB00215">Citalopram</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB00924">Cyclobenzaprine</a></td><td>Increased risk of toxicity with this association</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB06700">Desvenlafaxine</a></td><td>Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01191">Dexfenfluramine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB01576">Dextroamphetamine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00514">Dextromethorphan</a></td><td>Possible severe adverse reaction</td></tr><tr><td><a href="/drugs/DB00937">Diethylpropion</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00841">Dobutamine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00988">Dopamine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB00476">Duloxetine</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB01363">Ephedra</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01364">Ephedrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00668">Epinephrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01175">Escitalopram</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00574">Fenfluramine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB01288">Fenoterol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB01064">Isoprenaline</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00579">Mazindol</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB01365">Mephentermine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00610">Metaraminol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01577">Methamphetamine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00723">Methoxamine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00422">Methylphenidate</a></td><td>Possible hypertensive crisis with this combination.</td></tr><tr><td><a href="/drugs/DB00211">Midodrine</a></td><td>Risk of hypertensive crisis.</td></tr><tr><td><a href="/drugs/DB04896">Milnacipran</a></td><td>Increase serotonin levels. Combination therapy is contraindicated.  </td></tr><tr><td><a href="/drugs/DB00370">Mirtazapine</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00368">Norepinephrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB00816">Orciprenaline</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00454">Pethidine</a></td><td>Increased risk of serotonin syndrome. Concomitant use should be avoided.</td></tr><tr><td><a href="/drugs/DB01579">Phendimetrazine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00830">Phenmetrazine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00191">Phentermine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00388">Phenylephrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00397">Phenylpropanolamine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01291">Pirbuterol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01366">Procaterol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00344">Protriptyline</a></td><td>Possibility of severe adverse effects</td></tr><tr><td><a href="/drugs/DB00852">Pseudoephedrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01001">Salbutamol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01104">Sertraline</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB01105">Sibutramine</a></td><td>Possible serotoninergic syndrome with this combination</td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>Increased risk of toxicity with this association</td></tr><tr><td><a href="/drugs/DB06204">Tapentadol</a></td><td>Increases the toxicity of tapentadol by unknown mechanism. Discontinue rasagiline at least 14 days prior to tapentadol administration. </td></tr><tr><td><a href="/drugs/DB00871">Terbutaline</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB04844">Tetrabenazine</a></td><td>Tetrabenazine may increase the adverse/toxic effects of Rasagiline. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00323">Tolcapone</a></td><td>Tolcapone and Rasagiline decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects. </td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, rasagiline.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.</td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00315">Zolmitriptan</a></td><td>The MAO inhibitor, rasagiline, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing rasagiline are contraindicated. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol and caffeine.</li></ul></td></tr></tbody></table>